Insider Transactions in Q4 2021 at Cerevel Therapeutics Holdings, Inc. (CERE)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,127
-67.58%
|
$144,445
$35.0 P/Share
|
|
Dec 27
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+40.33%
|
$12,381
$3.5 P/Share
|
|
Dec 23
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,873
-74.79%
|
$205,555
$35.0 P/Share
|
|
Dec 23
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,873
+42.79%
|
$17,619
$3.5 P/Share
|
|
Dec 21
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,300
-78.66%
|
$233,600
$32.5 P/Share
|
|
Dec 21
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,300
+44.03%
|
$21,900
$3.5 P/Share
|
|
Dec 17
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,122
-78.25%
|
$227,904
$32.5 P/Share
|
|
Dec 17
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,122
+43.9%
|
$21,366
$3.5 P/Share
|
|
Dec 16
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,578
-73.8%
|
$178,496
$32.5 P/Share
|
|
Dec 16
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,578
+42.46%
|
$16,734
$3.5 P/Share
|
|
Dec 15
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.66%
|
$750,000
$30.02 P/Share
|
|
Dec 15
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.1%
|
$75,000
$3.5 P/Share
|
|
Nov 10
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
55,000
-57.74%
|
$2,200,000
$40.48 P/Share
|
|
Nov 10
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+50.0%
|
$165,000
$3.5 P/Share
|